Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

Ville, not disagreeing with some of what you say such as

this company has the worst Investor relations and public relations i have ever seen. No answers to questions. Not present for retail investors. Very often wrong and misleading forward looking statements. Lead to shareholder lawsuits in some cases.

I’ve seen multiple small companies act this way but the only thing that bothers me, and I’m wary about is

Very often wrong and misleading forward looking statements

I see this in the Rolontis BLA submission delay to the end of 2018. Based on the last pt dosed in beginning of September of 2017, in my book, it seems like they delayed by a year submitting the BLA. I have my reasons on why but I won’t get into it since it’s all speculation on my part but I can tell you it’s not based on the Spectrum CMC group being incompetent as someone on this board speculated. Another example is Dr Raj, when asked at a recent CC on the status of the EGFR compassionate use patient (on compassionate use because Her ECOG performance level was 4 whereas you needed to be 0 or 1 to enter the trial), said ‘Good’. Yes, the drug showed positive benefits but we also know she succumbed. Can’t he just state that.

But where I differ with you is at what price to sell at. If Ariad was bought by Takeda for $5.2B and at the time analysts were predicting Inclusig sales at $500M at peak I can easily see Spectrum going to $40 per share in a couple of years just on Poziotinib alone. Add Rolontis to the mix and perhaps apaziquone and revenue from existing drugs and I see the share price easily surpassing that. So as long as the news on Pozi continues to br positive I will do most of my selling above $40. Will sell some shares to live on but that’s hopefully not much. What I am counting on is the P3 NWBOs DCVax-L trial, with news possible occurring any day to the next 6 months, is positive (I’m down 85% on the stock at the moment) and if so, look at other stocks such as the ones you suggest. But in the meantime, I’ll keep a couple of those on my watch list.